Form 4 for NVAX NOVAVAX INC
Accepted 2021-12-16 00:00:00 ET · period of report 2021-12-14 · accession 0001209191-21-070007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-16 | 2021-12-14 | NVAX | Erck Stanley C | Pres, CEO, Dir | M - OptEx | — | +6,967 | 30.8K | +29% | — |
| D | 2021-12-16 | 2021-12-14 | NVAX | Erck Stanley C | Pres, CEO, Dir | F - Tax | $168.43 | -3,366 | 27.5K | -11% | -$566.9K |
| D | 2021-12-16 | 2021-12-14 | NVAX | Erck Stanley C | Pres, CEO, Dir | M - OptEx | $0.00 | -6,967 | 13.9K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-14 | M | A | 6,967 | — | 30,846 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| 2 | Common | Common Stock | 2021-12-14 | F | D | 3,366 | $168.43 | 27,480 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2021-12-14 | M | D | 6,967 | $0.00 | 13,933 | D | — · — to — | 6,967 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. (F2) The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. |